Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997749 | 0.90 | LTA4H (0.67) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL3011066 | 0.86 | LTA4H (0.55) | LTA4HHTTHRH3KDM4ESMN1; SMN2 | |
| SCHEMBL13213110 | 0.85 | LTA4H (0.63) | LTA4HHTTHRH3MCHR1 | |
| SCHEMBL13213294 | 0.84 | HRH3 (0.52) | LTA4HHRH3SMN1; SMN2MCHR1ALDH1A1 | |
| SCHEMBL2998200 | 0.82 | FFAR1 (0.43) | LTA4HHTTNPC1RAB9AKDM4E | |
| SCHEMBL3007724 | 0.79 | MCHR1 (0.51) | LTA4HHRH3SMN1; SMN2MCHR1ALDH1A1 | |
| SCHEMBL3009333 | 0.78 | LTA4H (0.65) | LTA4HHRH3MCHR1 | |
| Trifluoroacetic Acid SCHEMBL3003563 | 0.78 | LTA4H (0.53) | LTA4HHTTHRH3NPC1RAB9A | |
| SCHEMBL3006052 | 0.77 | FFAR1 (0.39) | LTA4HHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2476820 | 0.76 | LTA4H (1.00) | LTA4HHTTHRH3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| EP-2102171-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | LTA4H 2623/4885HTT 1601/4885HRH3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.